Results 51 to 60 of about 20,750 (203)
Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas [PDF]
, 2018 FDA-approved BRAF inhibitors produce high response rates and improve overall survival in patients with BRAF V600E/K-mutant melanoma, but are linked to pathologies associated with paradoxical ERK1/2 activation in wild-type BRAF cells.
Aplin, Andrew E. +10 more
core +1 more source
A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies [PDF]
, 2020 With recent advancements in the understanding of vitiligo pathogenesis, Janus kinase (JAK) inhibitors have emerged as a promising new treatment modality, but their effects remain incompletely elucidated.
Alikhan, Mujahed +4 more
core
British Journal of Clinical Pharmacology, EarlyView.Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang +6 more
wiley +1 more source
Case Reports in Oncological Medicine, 2020 Background. Metaplastic breast carcinomas are rare and carry poor prognoses. They are also more aggressive than other breast cancers and are known for their resistance to chemotherapy.
Takuji Seo +9 more
doaj +1 more source
Extended two-stage adaptive designswith three target responses forphase II clinical trials [PDF]
, 2017 We develop a nature-inspired stochastic population-based algorithm and call it discrete particle swarm optimization tofind extended two-stage adaptive optimal designs that allow three target response rates for the drug in a phase II trial.Our proposed ...
Kim, Seongho, Wong, Weng Kee
core +1 more source
Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs
Clinical Pharmacology &Therapeutics, EarlyView.Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri +10 more
wiley +1 more source
Sorafenib inhibits therapeutic induction of necroptosis in acute leukemia cells [PDF]
, 2017 Induction of necroptosis has emerged as an alternative approach to trigger programmed cell death, in particular in apoptosis-resistant cancer cells.
Feldmann, Friederike +4 more
core +3 more sources
Ocular toxicity due to Trametinib and Dabrafenib
BMC Ophthalmology, 2017 Background To report a case of uveitis and neuroretinal detachment in a patient treated with Trametinib and Dabrafenib due to metastatic cutaneous melanoma stage IV.
Stephanie Sarny +3 more
doaj +1 more source
BRAF inhibitor and hairy cell leukemia-related transient acantholytic dermatosis [PDF]
, 2020 Grover disease (GD) is an acquired, nonfamilial, nonimmune mediated, transient or persistent acantholytic dermatosis. Herein, we present a 72-year-old man who had clinical and histopathologic findings of GD following two weeks of treatment with ...
Durkin, John R +3 more
core
Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma [PDF]
, 2015 Melanoma is the deadliest form of skin cancer and has an incidence that is rising faster than any other solid tumor. Metastatic melanoma treatment has considerably progressed in the past five years with the introduction of targeted therapy (BRAF and MEK ...
Amaria, Rodabe N. +5 more
core +1 more source